News

Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

CY6463 alleviated mitochondrial dysfunction and reduced inflammation in preclinical models of mitochondrial complex 1 deficiency Data provide support for ongoing…

2 years ago

Codexis Announces the Publication of Research Demonstrating Proof of Concept for Chemoenzymatic Site-Selective Bioconjugation of Native Peptides

Collaboration with Merck published in Science magazine REDWOOD CITY, Calif., June 17, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS),…

2 years ago

VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

Top-line Efficacy Results Expected in Approximately 6 to 8 WeeksBRIDGEWATER, N.J., June 17, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc.…

2 years ago

Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil

Recent Company Submission in Response to FDA Request Extends PDUFA DateSOUTH SAN FRANCISCO, Calif., June 17, 2022 (GLOBE NEWSWIRE) --…

2 years ago

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022

Presentation to be highlighted in the Best of International Liver CongressGAITHERSBURG, Md., June 17, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc.…

2 years ago

Quotient Limited to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on June 22nd

JERSEY, Channel Islands, June 17, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that…

2 years ago

HEXO Acknowledges Zenabis Group CCAA Filing

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 2, 2022…

2 years ago

ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back…

2 years ago

U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

DENVER, June 17, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”),…

2 years ago

Stephen Bardin to Join atai Life Sciences as CFO Designate

Stephen Bardin will join as CFO Designate on June 27, 2022After a transition period, atai’s current CFO Greg Weaver will…

2 years ago